# Tata Memorial Centre

Source: https://onco.cc/institutions/tata-memorial/  
OnCo record `tata-memorial` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

India's largest cancer centre, a leader in low-cost, high-impact trials such as low-dose immunotherapy and oral metronomic chemotherapy.

## Summary

Tata Memorial Centre in Mumbai is India's largest cancer centre, seeing seventy thousand new patients a year, and a leader in low-cost, high-impact trials such as low-dose nivolumab with metronomic chemotherapy in head and neck cancer, visual cervical screening and affordable radiotherapy. Its trials in OnCo include elective versus therapeutic neck dissection in oral cancer, gefitinib with or without chemotherapy in EGFR-mutant lung cancer and the IARC India HPV vaccine dose study, and it anchors the National Cancer Grid of India and the CAR-T talicabtagene autoleucel from ImmunoACT. OnCo links it to bottlenecks on the absence of cancer care in most of the world and to ideas for a Global Fund for cancer care. Whether its low-cost regimens are adopted in richer countries is the open question. Its programmes are listed below.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Mumbai, IN
- Type: cancer-center
- Website: https://tmc.gov.in

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Tata_Memorial_Centre
- Official website: https://tmc.gov.in

## Connected records

- cancers: [Buccal mucosa and gingivobuccal cancer (oral cancer in India)](https://onco.cc/cancers/buccal-mucosa-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- trials: [Add-Aspirin](https://onco.cc/trials/add-aspirin/), [Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)](https://onco.cc/trials/elective-neck-dissection-tmh/), [Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)](https://onco.cc/trials/gefitinib-chemo-tmh/), [IARC India HPV vaccine dose study (one, two or three doses)](https://onco.cc/trials/iarc-india-hpv-dose-study/), [Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)](https://onco.cc/trials/low-dose-nivolumab-tmh/), [Low-dose olanzapine for cancer anorexia (Tata Memorial)](https://onco.cc/trials/olanzapine-appetite-tmh/), [METRO PLUS (Tata Memorial Centre, Varanasi)](https://onco.cc/trials/metro-plus-varanasi/), [Mumbai VIA cervical screening trial (Tata Memorial)](https://onco.cc/trials/mumbai-via-screening/), [Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)](https://onco.cc/trials/metronomic-vs-cisplatin-tmh/), [Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)](https://onco.cc/trials/osmanabad-hpv-screening/), [Peritumoral lidocaine before breast cancer surgery (Tata Memorial)](https://onco.cc/trials/lidocaine-peritumoral-tmh/), [POLCAGB](https://onco.cc/trials/polcagb/), [POP-RT](https://onco.cc/trials/pop-rt/), [RUGB](https://onco.cc/trials/rugb/), [Single-injection depot progesterone before breast surgery (Tata Memorial)](https://onco.cc/trials/progesterone-preop-tmh/), [Talicabtagene autoleucel (NexCAR19) phase 1/2](https://onco.cc/trials/talicel-phase-1-2/)
- people: [Akhil Kapoor](https://onco.cc/people/kapoor-akhil/), [Anil K. D'Cruz](https://onco.cc/people/dcruz-anil/), [C. S. Pramesh](https://onco.cc/people/pramesh-c-s/), [Gaurav Narula](https://onco.cc/people/narula-gaurav/), [Hasmukh Jain](https://onco.cc/people/jain-hasmukh/), [Kumar Prabhash](https://onco.cc/people/prabhash-kumar/), [Pankaj Chaturvedi](https://onco.cc/people/chaturvedi-pankaj/), [Rajendra Badwe](https://onco.cc/people/badwe-rajendra/), [Ratan Tata](https://onco.cc/people/ratan-tata/), [Sir Dorabji Tata](https://onco.cc/people/dorabji-tata/), [Sudeep Gupta](https://onco.cc/people/gupta-sudeep/), [Surendra Shastri](https://onco.cc/people/shastri-surendra/), [Vanita Noronha](https://onco.cc/people/noronha-vanita/), [Vijay Patil](https://onco.cc/people/patil-vijay/)
- key papers: [A National Cancer Grid pooled procurement initiative, India](https://onco.cc/key-papers/paper-pramesh-ncg-pooled-procurement-2023/), [A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol](https://onco.cc/key-papers/paper-polcagb-protocol-bmj-open-2019/), [Elective versus therapeutic neck dissection in node-negative oral cancer](https://onco.cc/key-papers/paper-dcruz-elective-neck-dissection-nejm-2015/), [Genomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population](https://onco.cc/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/), [Hospital-based gallbladder cancer registry from a high-volume referral cancer centre in India: Insights into epidemiology and roadmap for enhancing cancer care](https://onco.cc/key-papers/paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025/), [HPV screening for cervical cancer in rural India (Osmanabad)](https://onco.cc/key-papers/paper-sankaranarayanan-hpv-screening-nejm-2009/), [Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)](https://onco.cc/key-papers/paper-patil-low-dose-nivolumab-jco-2023/), [Single-injection depot progesterone before surgery and survival in operable breast cancer](https://onco.cc/key-papers/paper-badwe-progesterone-jco-2011/), [Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study](https://onco.cc/key-papers/paper-jain-talicabtagene-lancet-haem-2025/), [Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis](https://onco.cc/key-papers/paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/), [Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on](https://onco.cc/roadmaps/trial-modernisation-roadmap/)
- ideas: [A cheap old tablet to restore appetite](https://onco.cc/ideas/idea-bio2-low-dose-olanzapine-appetite/), [A Global Fund for cancer care in low- and middle-income countries](https://onco.cc/ideas/idea-fund-global-cancer-fund/), [A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers](https://onco.cc/ideas/idea-acc-metronomic-lmic-platform-trial/), [A randomised trial of adjuvant chemoradiation after margin-positive or node-positive gallbladder cancer resection](https://onco.cc/ideas/idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive/), [Blended finance and a low-cost linac to close the global radiotherapy gap](https://onco.cc/ideas/idea-fund-lmic-radiotherapy-finance/), [Burden-matched funding for trials led in low- and middle-income countries](https://onco.cc/ideas/idea-fund-lmic-burden-match/), [Community health workers with smartphone AI screen for mouth cancer in South Asia](https://onco.cc/ideas/idea-prev-oral-cancer-community-smartphone-ai/), [Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide](https://onco.cc/ideas/idea-reg-olanzapine-cachexia-global-confirmation/), [Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live](https://onco.cc/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/), [Double oncology capacity in low-resource settings with task-shifting and AI decision support](https://onco.cc/ideas/idea-moon-task-shifting-ai-oncology-capacity/), [National hub-and-spoke cancer networks with defined referral tiers](https://onco.cc/ideas/idea-acc-hub-spoke-national-networks/), [Paid survivor peer-navigators as a recognised health workforce role](https://onco.cc/ideas/idea-moon-peer-navigator-workforce/), [Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded](https://onco.cc/ideas/idea-tr1-lmic-sites-in-pivotal-trials/), [Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000](https://onco.cc/ideas/idea-reg-lmic-public-cart-manufacturing/), [Regional training hubs that produce oncologists, physicists and radiographers in-region](https://onco.cc/ideas/idea-acc-regional-oncology-training-hubs/), [Risk-targeted ultrasound screening in high-incidence regions, tested against usual care](https://onco.cc/ideas/idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions/), [Test one-tenth-dose immunotherapy where the full dose is unaffordable](https://onco.cc/ideas/idea-cost-low-dose-immunotherapy-trials/), [Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines](https://onco.cc/ideas/idea-reg-metronomic-lmic-phase3-to-label/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Not enough oncologists, nurses, pathologists, physicists](https://onco.cc/bottlenecks/b-workforce/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- technologies: [Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine](https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/), [Global oncology and access in low- and middle-income countries](https://onco.cc/technologies/global-oncology-access/), [Visual inspection with acetic acid (VIA) for cervical screening](https://onco.cc/technologies/via-cervical-screening/)
- institutions: [Advanced Centre for Treatment, Research and Education in Cancer](https://onco.cc/institutions/actrec/), [Central Drugs Standard Control Organization](https://onco.cc/institutions/cdsco/), [Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi](https://onco.cc/institutions/homi-bhabha-cancer-hospital-varanasi/), [Indian Institute of Technology Bombay](https://onco.cc/institutions/iit-bombay/), [National Cancer Grid of India](https://onco.cc/institutions/national-cancer-grid/), [National Centre for Biological Sciences](https://onco.cc/institutions/ncbs/), [National Health Authority (Ayushman Bharat PM-JAY)](https://onco.cc/institutions/nha-pmjay/), [Tata Medical Center, Kolkata](https://onco.cc/institutions/tata-medical-center-kolkata/), [Tata Trusts](https://onco.cc/institutions/tata-trusts/)
- companies: [ImmunoACT](https://onco.cc/companies/immunoact/)
- drugs: [Talicabtagene autoleucel](https://onco.cc/drugs/talicabtagene-autoleucel/)

---
JSON: https://onco.cc/api/v1/entities/tata-memorial.json